nach oben

European Journal of Nuclear Medicine and Molecular Imaging

Erschienen in:

01.05.2006 | Original article

First preclinical evaluation of mono-[¹²³I]iodohypericin as a necrosis-avid tracer agent

verfasst von: Yicheng Ni, Dieter Huyghe, Kristin Verbeke, Peter A. de Witte, Johan Nuyts, Luc Mortelmans, Feng Chen, Guy Marchal, Alfons M. Verbruggen, Guy M. Bormans

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 5/2006

Einloggen, um Zugang zu erhalten

Abstract

Purpose

We have labelled hypericin, a polyphenolic polycyclic quinone found in St. John’s wort (Hypericum perforatum), with¹²³I and evaluated mono-[¹²³I]iodohypericin (MIH) as a potential necrosis-avid diagnostic tracer agent.

Methods

MIH was prepared by an electrophilic radioiodination method. The new tracer agent was evaluated in animal models of liver infarction in the rat and heart infarction in the rabbit using single-photon emission computed tomography (SPECT), triphenyltetrazolium chloride (TTC) histochemical staining, serial sectional autoradiography and microscopy, and radioactivity counting techniques.

Results

Using in vivo SPECT imaging, hepatic and cardiac infarctions were persistently visualised as well-defined hot spots over 48 h. Preferential uptake of the tracer agent in necrotic tissue was confirmed by perfect match of images from post-mortem TTC staining, autoradiography (ARX) and histology. Radioactivity concentration in infarcted tissues was over 10 times (liver; 3.51% ID/g in necrotic tissue vs 0.38% ID/g in normal tissue at 60 h p.i.) and over 6 times (myocardium; 0.36% ID/g in necrotic tissue vs 0.054% ID/g in normal tissue; ratios up to 18 for selected parts on ARX images) higher than in normal tissues.

Conclusion

The results suggest that hypericin derivatives may serve as powerful necrosis-avid diagnostic agents for assessment of tissue viability.

Flotats A, Carrió I. Non-invasive in vivo imaging of myocardial apoptosis and necrosis. Eur J Nucl Med Mol Imaging 2003;30:615–630PubMedCrossRef

Buja LM, Tofe AJ, Kulkarni PV, Mukherjee A, Parkey RW, Francis MD, et al. Sites and mechanisms of localization of technetium-99m phosphorous radiopharmaceuticals in acute myocardial infarcts and other tissues. J Clin Invest 1977;60:724–740PubMedCrossRef

Khaw BA, Gold HK, Yasuda T, Leinbach RC, Kanke M, Fallon JT, et al. Scintigraphic quantification of myocardial necrosis in patients after intravenous injection of cardiac myosin specific antibody. Circulation 1986;74:501–508PubMed

Khaw BA, Yasuda T, Gold HK, Leinbach RC, Johns JA, Kanke M, et al. Acute myocardial infarction imaging with indium-111 labeled monoclonal antimyosin Fab fragments. J Nucl Med 1987;28:1671–1678PubMed

Khaw BA, Fallon JT, Beller GA, Haber E. Specificity of localization of myosin-specific antibody fragments in experimental myocardial infarction: histologic, histochemical, autoradiographic and scintigraphic studies. Circulation 1979;60:1527–1531PubMed

Khaw BA, Scott J, Fallon JT, Cahill SL, Haber E, Homcy C. Myocardial injury: quantitation by cell sorting initiated with antimyosin fluorescent spheres. Science 1982;217:1050–1053PubMedCrossRef

Khaw BA. The current role of infarct avid imaging. Semin Nucl Med 1999;29:259–270PubMedCrossRef

Frist W, Yasuda T, Segall G, Khaw BA, Strauss HW, Gold H, et al. Noninvasive detection of human cardiac transplant rejection with indium-111 anti-myosin (Fab) imaging. Circulation 1987;76:81–85

Ballester M, Obrador D, Carrio I, Auge JM, Moya C, Ponsllado G, et al. ¹¹¹In-monoclonal antimyosin antibody studies after the first year of heart transplantation: identification of risk groups for developing rejection during long-term follow-up and clinical implications. Circulation 1990;82:2100–2108PubMed

10.

Olmos RAV, Carrio I, Hoefnagel CA, Estorch M, Huinink WWT, Lopez-Pousa J, et al. High sensitivity of radiolabelled antimyosin scintigraphy in assessing anthracycline related early myocyte damage preceding cardiac dysfunction. Nucl Med Commun 2002;23:871–877CrossRef

11.

Dec GW, Palacios IF, Yasuda T, Fallon JT, Khaw BA, Strauss HW, et al. Antimyosin antibody cardiac imaging: its role in the diagnosis of myocarditis. J Am Coll Cardiol 1990;6:97–104

12.

Narula J, Khaw BA, Dec GW, Palacios IF, Southern JF, Fallon JT, et al. Recognition of acute myocarditis masquerading as acute myocardial infarction. N Engl J Med 1992;328:100–104CrossRef

13.

Obrador D, Ballester M, Carrio I, Auge JM, Lopez CM, Bosch I, et al. Active myocardial damage without attending inflammatory response in idiopathic dilated cardiomyopathy. J Am Coll Cardiol 1993;21:1667–1671PubMedCrossRef

14.

Obrador D, Ballester M, Carrió I, Moya C, Bosch I, Marti V, et al. Presence, evolving changes, and prognostic implications of myocardial damage detected in idiopathic and alcoholic dilated cardiomyopathy by ¹¹¹In monoclonal antimyosin antibodies. Circulation 1994;89:2054–2061PubMed

15.

Narula J, Petrov A, Pak KY, Lister BC, Khaw BA. Very early noninvasive detection of acute experimental nonreperfused myocardial infarction with ^99mTc-labeled glucarate. Circulation 1995;95:1577–1584

16.

Khaw BA, Nakazama A, O’Donell SM, Pak KY, Narula J. Avidity of technetium-99m glucarate for the necrotic myocardium: in vivo and in vitro assessment. J Nucl Cardiol 1997;4:283–290PubMedCrossRef

17.

Nelson J, Schmiedl U, Shankland E. Metalloporphyrins as tumor-seeking MRI contrast media and as potential selective treatment sensitizers. Invest Radiol 1990;25:S71–S73PubMed

18.

Ni Y, Marchal G, Yu J, Lukito G, Petre C, Wevers M, et al. Localization of metalloporphyrin induced “specific” enhancement in experimental liver tumors: a comparison between MRI, microangiographic and histologic findings. Acad Radiol 1995;2:687–699PubMedCrossRef

19.

Ni Y, Petré C, Miao Y, Yu J, Cresens E, Adriaens P, et al. Magnetic resonance imaging–histomorphologic correlation studies on paramagnetic metalloporphyrins in rat models of necrosis. Invest Radiol 1997;32:770–779PubMedCrossRef

20.

Maurer J, Strauss A, Ebert W, Bauer H, Felix R. Contrast-enhanced high resolution magnetic resonance imaging of pigmented malignant melanoma using Mn-TPPS4 and Gd-DTPA: experimental results. Melanoma Res 2000;10:40–46PubMedCrossRef

21.

Marchal G, Ni Y. Use of porphyrin-complex or expanded porphyrin-complex as an infarction localization diagnosticum. U.S. patent No. 6,013,241. 11 January 2000

22.

Marchal G, Ni Y, Herijgers P, Flameng W, Petre C, Bosmans H, et al. Paramagnetic metalloporphyrins: infarct avid contrast agents for diagnosis of acute myocardial infarction by magnetic resonance imaging. Eur Radiol 1996;6:2–8PubMedCrossRef

23.

Ni Y, Marchal G, Herijgers P, Flameng W, Petre C, Ebert W, et al. Paramagnetic metalloporphyrins: from enhancers for malignant tumors to markers of myocardial infarcts. Acad Radiol 1996;3:S395–S377PubMedCrossRef

24.

Herijgers P, Laycock SK, Ni Y, Marchal G, Bogaert J, Bosmans H, et al. Localization and determination of infarct size by Gd-mesoporphyrin enhanced MRI in dogs. Int J Cardiac Imaging 1997;13:499–507CrossRef

25.

Ni Y, Pislaru C, Bosmans H, Pislaru S, Miao Y, Van de Werf F, et al. Validation of intracoronary delivery of metalloporphyrin as an in vivo “histochemical staining” for myocardial infarction with MR imaging. Acad Radiol 1998;5:S37–41PubMedCrossRef

26.

Stillman AE, Wilke N, Jerosch-Herold M. Myocardial viability. Radiol Clin North Am 1999;37:361PubMedCrossRef

27.

Pislaru SV, Ni Y, Pislaru C, Bosmans H, Miao Y, Bogaert J, et al. Noninvasive measurements of infarct size after thrombolysis with a necrosis-avid MRI contrast agent. Circulation 1999;99:690–696PubMed

28.

Saeed M, Bremerich J, Wendland MF, Wyttenbach R, Weinmann HJ, Higgins CB. Reperfused myocardial infarction as seen with use of necrosis-specific versus standard extracellular MR contrast media in rats. Radiology 1999;213:247–57PubMed

29.

Lim TH, Choi SI. MRI of myocardial infarction. J Magn Reson Imaging 1999;10:686–693PubMedCrossRef

30.

Wendland MF, Saeed M, Lund G, Higgins CB. Contrast-enhanced MRI for quantification of myocardial viability. J Magn Reson Imaging 1999;10:694–702PubMedCrossRef

31.

Choi SI, Choi SH, Kim ST, Lim KH, Lim CH, Gong GY, et al. Irreversibly damaged myocardium at MR imaging with a necrotic tissue-specific contrast agent in a cat model. Radiology 2000;215:863–868PubMed

32.

Lee SS, Goo HW, Park SB, Lim CH, Gong GY, Seo LB, et al. MR imaging of reperfused myocardial infarction: comparison of necrosis-specific and intravascular contrast agents in a cat model. Radiology 2003;226:739–747PubMedCrossRef

33.

Ni Y, Miao Y, Bosmans H, Marchal GJ, Semmler W, Baert AL. Evaluation of interventional liver tumor ablation with Gd-mesoporphyrin enhanced magnetic resonance imaging. Radiology 1997;205:P319

34.

Pass HI. Photodynamic therapy in oncology: mechanisms and clinical use. J Natl Cancer Inst 1993;85:443–456PubMedCrossRef

35.

Chen B, Zupko I, De Witte PA. Photodynamic therapy with hypericin in a mouse P388 tumor model: vascular effects determine the efficacy. Int J Oncol 2001;18:737–742PubMed

36.

Vanbilloen H, Bormans G, Chen B, de Witte P, Verbruggen A, Verbeke K. Synthesis and preliminary evaluation of mono-[¹²³I]iodohypericin. J Labelled Compd Radiopharm 2001;44:S965–967CrossRef

37.

Ni Y, Adzamli K, Miao Y, Cresens E, Yu J, Periasamy MP, et al. MRI contrast enhancement of necrosis by MP-2269 and Gadophrin-2 in a rat model of liver infarction. Invest Radiol 2001;36:97–103PubMedCrossRef

38.

Ni Y, Dymarkowski S, Chen F, Bogaert J, Marchal G. Occlusive myocardial infarction: enhanced or not enhanced with necrosis avid contrast agents at magnetic resonance imaging. Radiology 2002;225:603–605PubMedCrossRef

39.

Rude R, Parkey RW, Bonte FJ, Twieg D, Lewis S, Pulido J, et al. Clinical implications of the “doughnut” pattern of uptake in myocardial imaging with technetium-99m stannous pyrophosphate. Circulation 1977;56:146

40.

Lavie G, Mazur Y, Lavie D, Meruelo D. The chemical and biological properties of hypericin: a compound with a broad spectrum of biological activities. Med Res Rev 1995;15:111–119PubMedCrossRef

Titel: First preclinical evaluation of mono-[123I]iodohypericin as a necrosis-avid tracer agent
verfasst von: Yicheng Ni
Dieter Huyghe
Kristin Verbeke
Peter A. de Witte
Johan Nuyts
Luc Mortelmans
Feng Chen
Guy Marchal
Alfons M. Verbruggen
Guy M. Bormans
Publikationsdatum: 01.05.2006
Verlag: Springer-Verlag
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 5/2006
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-005-0013-2

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2006

Fully automatic diagnostic system for early- and late-onset mild Alzheimer’s disease using FDG PET and 3D-SSP

Role of 18F-FDG PET/CT in the assessment of bone involvement in newly diagnosed multiple myeloma: preliminary results

Imaging of primary breast cancer with 18F-fluorodeoxythymidine PET-CT reveals heterogeneity of proliferation throughout the tumour

Respiratory gating of cardiac PET data in list-mode acquisition

Developing nuclear medicine in developing countries: IAEA’s possible mission

Scintigraphic appearance of “linitis plastica” in a patient with gastric non-Hodgkin’s lymphoma on 18F-FDG imaging